COMP <GO>
ABUS vs ANL // EV/EBITDA & P/E VALUATION
Arbutus Biopharma Corporation (NASDAQ) VS. Adlai Nortye Group Ltd. (NASDAQ) • 15-METRIC TALLY: ABUS 1
— ANL 1
■ METRIC PARITY
LAST: $4.28 (-0.93%) • MKT CAP: $656.0M
valuation
—
LAST: $10.28 (+0.78%) • MKT CAP: $662.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABUS VS. ANL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABUS | ANL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.04% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 128.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.34 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.9 | 31.6 | +8.32 | ABUS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $656.0M | $662.0M | -$6.0M | ANL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABUS REV | ANL REV | ABUS GROSS % | ANL GROSS % | ABUS FCF | ANL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.1M | — | — | — | -$39.6M | — |
| FY 2024 | $6.2M | — | — | — | -$65.0M | — |
| FY 2023 | $18.1M | — | — | — | -$85.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABUS // BETA —
ANL // BETA —